MX2015010937A - Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas. - Google Patents

Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.

Info

Publication number
MX2015010937A
MX2015010937A MX2015010937A MX2015010937A MX2015010937A MX 2015010937 A MX2015010937 A MX 2015010937A MX 2015010937 A MX2015010937 A MX 2015010937A MX 2015010937 A MX2015010937 A MX 2015010937A MX 2015010937 A MX2015010937 A MX 2015010937A
Authority
MX
Mexico
Prior art keywords
mobilization
homing
differentiation
expansion
methods
Prior art date
Application number
MX2015010937A
Other languages
English (en)
Spanish (es)
Inventor
David Bar-Or
Greg Thomas
Original Assignee
Ampio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampio Pharmaceuticals Inc filed Critical Ampio Pharmaceuticals Inc
Publication of MX2015010937A publication Critical patent/MX2015010937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015010937A 2013-03-15 2014-03-17 Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas. MX2015010937A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361791623P 2013-03-15 2013-03-15
US201361832713P 2013-06-07 2013-06-07
US201361897449P 2013-10-30 2013-10-30
US201461923314P 2014-01-03 2014-01-03
US201461939625P 2014-02-13 2014-02-13
PCT/US2014/030538 WO2014145729A2 (en) 2013-03-15 2014-03-17 Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same

Publications (1)

Publication Number Publication Date
MX2015010937A true MX2015010937A (es) 2015-10-29

Family

ID=51538532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010937A MX2015010937A (es) 2013-03-15 2014-03-17 Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.

Country Status (15)

Country Link
US (3) US9808454B2 (https=)
EP (1) EP2968315B1 (https=)
JP (1) JP6588005B2 (https=)
KR (1) KR20150132508A (https=)
CN (1) CN105101965B (https=)
AU (1) AU2014232728B2 (https=)
BR (1) BR112015020469A2 (https=)
CA (1) CA2906864A1 (https=)
EA (1) EA201500943A1 (https=)
IL (1) IL240473A0 (https=)
MX (1) MX2015010937A (https=)
PH (1) PH12015502048A1 (https=)
SG (2) SG11201506267XA (https=)
WO (1) WO2014145729A2 (https=)
ZA (1) ZA201507291B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) * 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CA2958080A1 (en) * 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
EP3461887A4 (en) 2016-03-09 2020-01-22 University Of Ulsan Foundation For Industry Cooperation COMPOSITION FOR PROLIFERATION, PROMOTION OF DIFFERENTIATION OR SENESCENCE INHIBITION OF STEM CELLS WITH JAK1 INHIBITOR AS AN ACTIVE SUBSTANCE
WO2017160986A1 (en) * 2016-03-16 2017-09-21 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN107418934B (zh) * 2016-05-24 2021-01-01 南开大学 Tnfsf15蛋白在人脐带血造血干细胞体外扩增中的用途
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN106834223B (zh) * 2017-04-05 2020-03-27 上海逍鹏生物科技有限公司 诱导脐带间充质干细胞向软骨细胞分化的方法
CN112094804B (zh) * 2019-06-18 2024-05-14 中国医学科学院基础医学研究所 一种异质性干细胞群、其制备方法及用途
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
WO2021163693A1 (en) * 2020-02-16 2021-08-19 Pur Biologics, Inc. Methods of manufacturing extracellular matrix using aspartyl alanyl diketopiperazine (da-dkp)
KR102545746B1 (ko) * 2020-12-03 2023-06-20 가톨릭대학교 산학협력단 유도만능줄기세포 유래 혈관세포 및 SDF1a를 발현하는 중간엽 줄기세포를 포함하는 심장 재생용 조성물
CN112657048B (zh) * 2021-01-26 2024-04-02 南方科技大学 一种非手性磁控微型机器人及其制备方法和应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114717184B (zh) * 2022-05-05 2023-04-21 中国水产科学研究院北戴河中心实验站 一种牙鲆精原干细胞培养液及建立牙鲆精原干细胞系的方法
WO2024051847A1 (zh) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 用于防治面部神经微卡压综合征的药物组合物及其应用
CN120699894A (zh) * 2024-03-25 2025-09-26 中国科学院分子细胞科学卓越创新中心 Clusterin阳性心脏类器官及其应用
CN119020264A (zh) * 2024-10-12 2024-11-26 中国医学科学院北京协和医院 咽鼓管黏膜上皮细胞的获取及培养方法

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
FR2092556A5 (https=) 1970-04-02 1972-01-21 Snam Progetti
GB1353304A (en) 1971-03-30 1974-05-15 Sagami Chem Res Process for production of diketopiperazine dihydroxamates and intermediate therefor
US4006261A (en) 1973-09-28 1977-02-01 Firmenich S.A. Flavoring with mixtures of theobromine and cyclic dipeptides
US3928330A (en) 1973-12-19 1975-12-23 Ciba Geigy Corp Substituted piperazinedione carboxylic acids and metal salts thereof
GB1459488A (en) 1974-03-19 1976-12-22 Wyeth John & Brother Ltd Piperazinedione derivatives
US4088649A (en) 1975-07-02 1978-05-09 Firmenich S.A. Process for preparing a diketo-piperazine
JPS5225019A (en) 1975-08-19 1977-02-24 New Zealand Inventions Dev Production of serum albumin
US4205057A (en) 1978-01-17 1980-05-27 Government Of The United States Cerebrospinal fluid protein fragments
DE2940654A1 (de) 1979-10-06 1981-04-16 Bayer Ag, 5090 Leverkusen Dimeres keten der 1,2,,-triazol-3-carbonsaeure
US4331595A (en) 1980-06-23 1982-05-25 Ortho Pharmaceutical Corporation Immunoregulatory diketopiperazine compounds
US4289759A (en) 1980-06-23 1981-09-15 Ortho Pharmaceutical Corporation Immunoregulatory diketopiperazine compounds
JPS5836225U (ja) 1981-08-31 1983-03-09 株式会社東芝 金属製平パレツト
JPS5973574A (ja) 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
US4694061A (en) 1983-10-12 1987-09-15 Ciba-Geigy Corporation Radiation-sensitive polycondensates, processes for their preparation coated material and its use
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US4806538A (en) 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
JPS61112060A (ja) 1984-11-02 1986-05-30 Fujisawa Pharmaceut Co Ltd ピペラジン化合物
CS254868B1 (cs) 1985-06-11 1988-02-15 Jiri Vanzura Způsob výroby cyklických dipeptidů
JPS6236331A (ja) 1985-08-12 1987-02-17 Kenji Suzuki 抗感染症剤ならびに免疫賦活剤
US4661500A (en) 1985-08-29 1987-04-28 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US4771056A (en) 1985-08-29 1988-09-13 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US5047401A (en) 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
US4694081A (en) 1985-09-23 1987-09-15 Monsanto Company Process to prepare 2,5-diketopiperazines
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
JPS63290868A (ja) 1987-05-22 1988-11-28 Fujisawa Pharmaceut Co Ltd ジケトピペラジン誘導体およびその塩類
JPS6413075A (en) 1987-07-03 1989-01-17 Nippon Chemiphar Co Production of 2, 5-piperazinedione derivative
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US4992552A (en) 1988-08-31 1991-02-12 Eastman Kodak Company Process for preparation of amino acids
US5144073A (en) 1988-08-31 1992-09-01 Hubbs John C Process for preparation of dipeptides
JP2001055340A (ja) 1988-10-31 2001-02-27 Welfide Corp アルブミン製剤の製造方法
US5238938A (en) 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
DE3906952A1 (de) 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
DE68922102T2 (de) 1989-10-13 1995-10-19 Phobos Nv Verfahren zur kontinuierlichen Herstellung von hochmolekularen Polyester-Harzen.
JPH03176478A (ja) 1989-12-05 1991-07-31 Snow Brand Milk Prod Co Ltd 新規なジケトピペラジン誘導体及びこれを有効成分とする免疫抑制剤
CA2060515A1 (en) 1990-03-15 1991-09-16 John B. Hill Process for manufacturing aspartame from a diketopiperazine and novel intermediates and derivatives therefor
US6180616B1 (en) 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU646522B2 (en) 1990-11-14 1994-02-24 University Company Pty Limited, The Diagnosis and treatment of multiple sclerosis
US5776892A (en) 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
JPH04234374A (ja) 1990-12-27 1992-08-24 Ajinomoto Co Inc ジケトピペラジン誘導体の製造方法
GB9102997D0 (en) 1991-02-13 1991-03-27 Pfizer Ltd Therapeutic agents
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5538993A (en) 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
WO1993008815A1 (en) 1991-10-28 1993-05-13 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
JPH05163148A (ja) 1991-12-18 1993-06-29 Kanebo Ltd 抗腫瘍剤
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
JP3176478B2 (ja) 1992-05-29 2001-06-18 いすゞ自動車株式会社 居眠り運転防止装置
US5418218A (en) 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5358938A (en) 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5648486A (en) 1992-07-13 1997-07-15 Cytomed, Inc. Compounds and methods for the treatment of inflammatory and immune disorders
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
WO1994004537A2 (en) 1992-08-20 1994-03-03 Cytomed, Inc. Dual functional anti-inflammatory and immunosuppressive agents
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ATE244299T1 (de) 1992-12-18 2003-07-15 Molecular Rx Inc Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ES2068742B1 (es) 1993-02-11 1995-11-16 Uriach & Cia Sa J Nuevos derivados de piridinio.
AU6359594A (en) 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
WO1995003054A1 (en) 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Methods of treating apoptosis and associated conditions
GB9324872D0 (en) 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
IL112627A0 (en) 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
JP2921731B2 (ja) 1994-03-10 1999-07-19 日清製油株式会社 有機溶媒または油脂類のゲル化剤
FR2717484A1 (fr) 1994-03-16 1995-09-22 Pf Medicament Nouveaux composés pseudo-bis-peptidiques analogues de la CCK, leur procédé de préparation, leur utilisation à titre de médicament et les compositions pharmaceutiques les comprenant .
GB9410387D0 (en) 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
WO1996000391A1 (en) 1994-06-23 1996-01-04 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
US5990112A (en) 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5703093A (en) 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
EE9600184A (et) 1994-06-27 1997-06-16 Cytomed, Inc. Kardiovaskulaar-, inflammatoor- ja immuunhaiguste raviühendid ja -meetodid
US5750565A (en) 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
WO1996004268A1 (en) 1994-07-29 1996-02-15 Nikken Chemicals Co., Ltd. 1,4-dihydropyridine compound and medicinal composition containing the same
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
CA2200761C (en) 1994-10-05 2008-02-26 Cari Loder Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
ES2087038B1 (es) 1994-11-07 1997-03-16 Uriach & Cia Sa J Nuevas piperidinas con actividad antagonista del paf.
CZ282794A3 (en) 1994-11-16 1996-04-17 Galena Pentapeptidic precursors of biologically active cyclic dipeptides
US5877174A (en) 1994-12-01 1999-03-02 Toyama Chemical Co., Ltd. 2,3-diketopiperazine derivatives or their salts
JP3634891B2 (ja) 1995-04-06 2005-03-30 株式会社海洋バイオテクノロジー研究所 キチナーゼ阻害物質
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US5811241A (en) 1995-09-13 1998-09-22 Cortech, Inc. Method for preparing and identifying N-substitued 1,4-piperazines and N-substituted 1,4-piperazinediones
US5665714A (en) 1995-12-07 1997-09-09 Clarion Pharmaceuticals Inc. N-substituted glycerophosphoethanolamines
US6060452A (en) 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
CA2249604A1 (en) 1996-04-03 1997-10-09 Theresa M. Williams Inhibitors of farnesyl-protein transferase
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0896582A1 (en) 1996-04-03 1999-02-17 Pepresearch A/S Non-dendritic backbone peptide carrier
JP2000508645A (ja) 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
US5932579A (en) 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
US5985581A (en) 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
WO1998009968A1 (en) 1996-09-09 1998-03-12 Novartis Animal Health Australasia Pty. Limited Terpenylated diketopiperazines, (drimentines)
NZ335544A (en) 1996-10-04 2001-08-31 Neuronz Ltd Use of GPE (tripeptide or dipeptide) in form of Gly-Pro-Glu or Gly-Pro or Pro-Glu as a neuromodulator
RU2125728C1 (ru) 1996-10-10 1999-01-27 Пермская государственная медицинская академия Способ иммунодиагностики рассеянного склероза
EP0835660A1 (en) 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US5932112A (en) 1996-11-27 1999-08-03 Browning Transport Management, Inc. Method and apparatus for killing microorganisms in ship ballast water
RU2112242C1 (ru) 1996-12-09 1998-05-27 Пермская государственная медицинская академия Способ диагностики рассеянного склероза
JPH10226615A (ja) 1997-02-18 1998-08-25 Pola Chem Ind Inc アスパラギン酸フェニルアラニン環状ジペプタイド誘導体を含有する組成物
JPH10245315A (ja) 1997-03-05 1998-09-14 Pola Chem Ind Inc シクロジペプタイド誘導体を含有する組成物
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
AU6465798A (en) 1997-03-14 1998-09-29 Neuromark Diagnosing neurologic disorders
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
RU2128840C1 (ru) 1997-06-16 1999-04-10 Пермская государственная медицинская академия Способ диагностики рассеянного склероза
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
US5834032A (en) 1997-08-11 1998-11-10 Song; Moon K. Compositions and methods for treating diabetes
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
WO1999049865A1 (en) 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
EP1067951A2 (en) 1998-04-03 2001-01-17 Cytran Ltd. Use of l-glu-l-trp in the treatment of hiv infection
AU3467099A (en) 1998-04-03 1999-10-25 Cytran Ltd. Methods for production of therapeutic cytokines
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US6475743B1 (en) 1998-10-02 2002-11-05 Ischemia Technologies, Inc. Marker useful for detection and measurement of free radical damage and method
US6492179B1 (en) 1998-10-02 2002-12-10 Ischemia Techologies, Inc. Test for rapid evaluation of ischemic states and kit
US6461875B1 (en) 1998-10-02 2002-10-08 Ischemia Technologies, Inc. Test for rapid evaluation of ischemic states and kit
WO2000020840A1 (en) 1998-10-02 2000-04-13 Ischemia Technologies, Inc. Tests for the rapid evaluation of ischemic states and kits
DE69939121D1 (de) 1998-10-02 2008-08-28 Ischemia Tech Inc Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
CA2359561A1 (en) 1999-01-20 2000-07-27 Shiro Akinaga Proteasome inhibitors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU3760400A (en) 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6090780A (en) 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
JP2000327575A (ja) 1999-05-26 2000-11-28 Teika Seiyaku Kk ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
EP1276731A2 (en) 1999-11-12 2003-01-22 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US20050096323A1 (en) 1999-11-30 2005-05-05 Novoscience Pharma Inc. Diketopiperazine derivatives to inhibit thrombin
AU2001236005A1 (en) 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
DE10019879A1 (de) 2000-04-20 2001-10-25 Degussa Verfahren zur Herstellung von 2,5-Diketopiperazinen, neue 2,5-Diketopiperazine und deren Verwendung
US7288545B2 (en) 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
ATE417614T1 (de) 2000-05-09 2009-01-15 Angiorx Corp Piperazindion-verbindungen
DE10026998A1 (de) 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
WO2001094347A1 (en) 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
CZ20002680A3 (cs) 2000-07-21 2002-03-13 Ev®En Ing. Csc. Kasafírek Cyklické alkylthiopeptidy
CZ20002681A3 (cs) 2000-07-21 2002-03-13 Ev®En Ing. Csc. Kasafírek Cyklické tyrosinové dipeptidy
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
AU2001284697A1 (en) 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
AU2001297611A1 (en) 2000-12-29 2002-08-19 Celltech R And D, Inc. Pharmaceutical uses and synthesis of diketopiperazines
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
WO2002059604A2 (en) 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
MXPA03009378A (es) 2001-04-13 2004-01-29 Vertex Pharma Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas.
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
AU2002332122A1 (en) 2001-10-15 2003-04-28 The Medstar Research Institute Modulation of akt-dependent response to prevent restenosis
EP1575976A4 (en) 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
EP2460884A3 (en) 2001-12-27 2013-03-27 Ajinomoto Co., Inc. Process for preparing monatin
MXPA04006928A (es) 2002-01-18 2004-12-06 Unilever Nv Composiciones cosmeticas comprendiendo un compuesto de ciclodipeptido.
JP2005537223A (ja) 2002-04-05 2005-12-08 ニトロメッド，インク． 酸化窒素供与体、組成物および使用法
ES2204294B2 (es) 2002-07-02 2005-02-01 Universidade De Santiago De Compostela Nuevos antibioticos activos frente al vibrio anguillarum y sus aplicaciones en cultivos de peces, crustaceos, moluscos y otras actividades de acuicultura.
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BR0313363A (pt) 2002-08-02 2005-08-09 Nereus Pharmaceuticals Inc Deidrofenilahistinas e seus análogos, e sua sìntese
KR20050042146A (ko) 2002-08-06 2005-05-04 아플라겐 게엠베하 결합 분자
DE10238144A1 (de) 2002-08-15 2004-02-26 Basf Ag Verwendung von Diketopiperazin-Derivaten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1537129B1 (en) 2002-09-03 2013-11-06 Georgetown University Akt inhibitors, pharmaceutical compositions, and uses thereof
NZ539735A (en) 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
US7196169B2 (en) 2002-10-11 2007-03-27 Queen's University At Kingston Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
CA2506843A1 (en) 2002-11-22 2004-06-10 Novo-Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
CN1791420A (zh) * 2003-05-15 2006-06-21 Dmi生物科学公司 T－细胞介导的疾病的治疗
EP1622633B1 (en) * 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
CN1829701A (zh) 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
JP4842817B2 (ja) 2003-09-03 2011-12-21 ニューレン ファーマシューティカルズ リミテッド 神経保護二環式化合物およびその使用方法
AU2005260077A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
MX2007002085A (es) 2004-08-20 2007-07-19 Prometic Biosciences Ltd Esquemas de aislamiento y purificacion consecutivos de proteinas mediante cromatografia de afinidad.
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN101115479A (zh) 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
CA2621595A1 (en) 2005-09-21 2007-04-12 Surmodics, Inc. Coatings and articles including natural biodegradable polysaccharides
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
US20080017576A1 (en) 2006-06-15 2008-01-24 Rensselaer Polytechnic Institute Global model for optimizing crossflow microfiltration and ultrafiltration processes
AR061240A1 (es) 2006-06-20 2008-08-13 Lilly Co Eli Compuestos de de 4-isoquinolin-fenol,composiciones farmaceuticas que los contienen y su uso como agentes antineoplasicos y/o antivirales.
EP2051725A4 (en) 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US8231929B2 (en) 2006-11-09 2012-07-31 Cook Medical Technologies Llc Medical device coating process
EP2173352B1 (en) 2007-07-12 2016-09-07 University of South Florida Inhibitors of akt/pkb with anti-tumor activity
US20090038416A1 (en) 2007-08-07 2009-02-12 Aleta Behrman Bonner System and method for biological sample collection and analyte detection
WO2009032651A1 (en) 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
MX2010003113A (es) 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
US20090163936A1 (en) 2007-12-21 2009-06-25 Chunlin Yang Coated Tissue Engineering Scaffold
US20100042206A1 (en) 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
US8383124B2 (en) 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US20110177043A1 (en) * 2008-09-22 2011-07-21 Agency for science,technology and research(A*star) Method of improving differentiation of chondrogenic progenitor cells
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102438602B (zh) 2009-03-04 2016-04-13 曼金德公司 改进的干燥粉末药物输送系统
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CN101914490B (zh) * 2010-08-13 2012-10-10 中国医科大学 一种人羊膜间充质干细胞无血清培养基及其培养方法
AU2011299353B2 (en) 2010-09-07 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of diseases
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
WO2012045094A1 (en) * 2010-10-01 2012-04-05 The Trustees Of Columbia University In The City Of New York Derivation of fibrochondrocytes from progenitor cells
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
JP3176478U (ja) 2012-04-11 2012-06-21 ネイス株式会社 運動用エアートランポリン
BR112015017958A2 (pt) 2013-02-01 2017-07-11 Ampio Pharmaceuticals Inc métodos para produzir dicetopiperazinas e composições contendo dicetopiperazinas
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Also Published As

Publication number Publication date
EP2968315A4 (en) 2016-08-31
IL240473A0 (en) 2015-09-24
NZ712630A (en) 2021-07-30
ZA201507291B (en) 2019-04-24
EP2968315A2 (en) 2016-01-20
SG11201506267XA (en) 2015-09-29
HK1214143A1 (zh) 2016-07-22
CN105101965A (zh) 2015-11-25
CN105101965B (zh) 2021-03-09
JP2016515533A (ja) 2016-05-30
AU2014232728A1 (en) 2015-10-29
EP2968315B1 (en) 2020-06-03
US11026940B2 (en) 2021-06-08
SG10201707619RA (en) 2017-10-30
PH12015502048A1 (en) 2016-01-18
WO2014145729A2 (en) 2014-09-18
EA201500943A1 (ru) 2016-08-31
US20140286913A1 (en) 2014-09-25
JP6588005B2 (ja) 2019-10-09
US20220016110A1 (en) 2022-01-20
AU2014232728B2 (en) 2019-02-21
CA2906864A1 (en) 2014-09-18
WO2014145729A3 (en) 2014-12-24
US20180153880A1 (en) 2018-06-07
BR112015020469A2 (pt) 2020-01-28
KR20150132508A (ko) 2015-11-25
US9808454B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MX2024004420A (es) Variantes de alfa-glucosidasa acida y usos de las mismas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EA201591615A1 (ru) Замещенные ксантины и способы их применения
AU2016263598A8 (en) Methods and kits for treating depression
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12017501864A1 (en) Compositions and methods for treating autism
AU2015311730A8 (en) CaMKII inhibitors and uses thereof